Or perhaps worse yet.... speaking out against? Tbh, that's the first thing that crossed my mind. Safe bet this ban didn't originate prior to 2020. ... whatever.
Fading a KR was easy on Friday because I made over $2.50+ on the BS NYSE low ball OPEN selling near $48. Next, why did I buy puts, a few of my most powerful Consumer Defense got smacked after a great Q and outlook. KR would get the same treatment as my other Defense was the theory.
Look who smoked earnings. Our old favorite. I thought about playing it, but I didn't. Look at a 10 or 15 year chart. Same quality as KR. $251.00 ---> +$11.60
Two Cdn Weed stocks today : WEED +81%, NDVA +57% ( US govt news ) Cdn Oil stocks today : Pulled back despite WTI being $87.27. Annoying given how slowly they rallied lately. Interesting to see what they all do tomorrow. Lucero ( small cap Oil ) didn't pull back. TSX Venture pretty lively lately.
Greetings Everyone. I am ok. The Giants were smashed 40 to 0 but I am ok. Things will get better HUMA <------- Humacyte, Inc Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will host a virtual webinar to announce top line data results from its Phase 2/3 V005 vascular trauma clinical trial. The V005 trial evaluated the HAV, an off-the-shelf, universally implantable bioengineered human tissue, in vascular trauma repair. The event will also feature Dr. Michael Curi (Rutgers University), who will discuss the unmet clinical need in vascular trauma, and the use of the HAV as a potential repair solution for patients and soldiers with limb- and life-threatening injuries. Dr. Curi has utilized the HAV and has participated in the V005 clinical trial.